EQT

Vico Therapeutics B.V. is a biotechnology company based in Leiden, the Netherlands, founded in 2019. The company specializes in the development of RNA modulating therapies aimed at treating rare neurological disorders. Vico Therapeutics focuses on conditions such as spinocerebellar ataxias, Huntington’s disease, and Rett syndrome, which encompass a range of hereditary and neurodevelopmental disorders. By discovering and developing innovative therapies, the company aims to address significant unmet medical needs in the central nervous system, providing new treatment options for patients and healthcare professionals.

Onward is a medical technology company focused on developing therapies aimed at enabling functional recovery for individuals with spinal cord injuries. The company is creating an Implantable Neuro-stimulation System (INS) that features real-time motion feedback and utilizes training tools for rehabilitation. Onward has developed two platforms for neurostimulation: ARCIM, an implantable system, and ARCEX, a non-invasive transcutaneous system. To establish its customer base, Onward has targeted the United States and four European markets, namely Germany, France, the United Kingdom, and the Netherlands.

Vico Therapeutics B.V. is a biotechnology company based in Leiden, the Netherlands, founded in 2019. The company specializes in the development of RNA modulating therapies aimed at treating rare neurological disorders. Vico Therapeutics focuses on conditions such as spinocerebellar ataxias, Huntington’s disease, and Rett syndrome, which encompass a range of hereditary and neurodevelopmental disorders. By discovering and developing innovative therapies, the company aims to address significant unmet medical needs in the central nervous system, providing new treatment options for patients and healthcare professionals.

Xeltis AG, established in 2006, is a clinical-stage medical device company based in Zurich, Switzerland, with additional operations in the Netherlands and the USA. The company specializes in developing bio-absorbable heart valves and blood vessels using a proprietary polymer-based technology. Xeltis' RestoreX platform enables the body's natural healing system to develop tissue that replaces the implant, forming a new functional valve or vessel. The company's restorative devices include implantable small diameter blood vessels for hemodialysis and coronary artery bypass graft (CABG) surgery, as well as pulmonary heart valves, with ongoing clinical trials. Xeltis has raised funding from various venture capital firms and European institutions, including a €30 million round in 2021.

Xeltis AG, established in 2006, is a clinical-stage medical device company based in Zurich, Switzerland, with additional operations in the Netherlands and the USA. The company specializes in developing bio-absorbable heart valves and blood vessels using a proprietary polymer-based technology. Xeltis' RestoreX platform enables the body's natural healing system to develop tissue that replaces the implant, forming a new functional valve or vessel. The company's restorative devices include implantable small diameter blood vessels for hemodialysis and coronary artery bypass graft (CABG) surgery, as well as pulmonary heart valves, with ongoing clinical trials. Xeltis has raised funding from various venture capital firms and European institutions, including a €30 million round in 2021.

Storytel is a leading provider of audiobook and e-book streaming services, offering unlimited access to a diverse range of titles across more than 20 markets. Founded in 2005 and headquartered in Sweden, the company operates under the Storytel and Mofibo brands, providing users with the ability to explore a wide array of genres, including detective stories, novels, and biographies, in multiple languages such as Swedish, English, Arabic, Danish, and Finnish. Storytel also has a significant publishing division that includes several established publishing houses, such as Norstedts, Massolit, and B. Wahlstrom, focusing on both adult and children's literature. The company has expanded its services internationally, with operations in countries like Denmark, Norway, the Netherlands, and the USA, positioning itself as a prominent player in the subscription-based audiobook and e-book market.

ViCentra B.V., based in Utrecht, the Netherlands, specializes in the development of medical devices, particularly for diabetes management. The company focuses on creating user-friendly and aesthetically pleasing products that aim to enhance the overall experience for individuals managing their health. ViCentra emphasizes the importance of excellent customer experiences and approaches product design with the belief that simplicity and effectiveness lead to better health outcomes. In addition to its operations in the Netherlands, ViCentra also has a presence in the UK, where it continues to innovate in the field of medical devices through dedicated research and development efforts.

Storytel is a leading provider of audiobook and e-book streaming services, offering unlimited access to a diverse range of titles across more than 20 markets. Founded in 2005 and headquartered in Sweden, the company operates under the Storytel and Mofibo brands, providing users with the ability to explore a wide array of genres, including detective stories, novels, and biographies, in multiple languages such as Swedish, English, Arabic, Danish, and Finnish. Storytel also has a significant publishing division that includes several established publishing houses, such as Norstedts, Massolit, and B. Wahlstrom, focusing on both adult and children's literature. The company has expanded its services internationally, with operations in countries like Denmark, Norway, the Netherlands, and the USA, positioning itself as a prominent player in the subscription-based audiobook and e-book market.

Mollie is a technology-driven payments platform based in Amsterdam, founded in 2004. It simplifies the integration of payment solutions for online merchants, processing transactions for over 50,000 clients. The platform supports a wide array of local payment methods, including major credit cards, PayPal, and various local banking options, as well as cryptocurrencies. Mollie's application features one-click payments, fraud monitoring, multicurrency support, daily settlement management, and real-time accounting, enabling businesses to streamline their operations and enhance revenue management. The company prioritizes innovation and reliability, aiming to make online payments straightforward and efficient for merchants.

Onward is a medical technology company focused on developing therapies aimed at enabling functional recovery for individuals with spinal cord injuries. The company is creating an Implantable Neuro-stimulation System (INS) that features real-time motion feedback and utilizes training tools for rehabilitation. Onward has developed two platforms for neurostimulation: ARCIM, an implantable system, and ARCEX, a non-invasive transcutaneous system. To establish its customer base, Onward has targeted the United States and four European markets, namely Germany, France, the United Kingdom, and the Netherlands.

NewAmsterdam Pharma, established in 2019 and headquartered in Naarden, the Netherlands, is a late-stage biopharmaceutical company dedicated to improving patient care in cardio-metabolic disease populations. The company's primary focus is the development of transformative therapies, with its lead product, obicetrapib, being a next-generation, oral, low-dose CETP inhibitor designed to lower LDL-C levels more effectively than current treatments, particularly for patients with statin intolerance or Arteriosclerotic Cardiovascular Disease/Familial Hypercholesterolemia (ASCVD/FH) on maximally-tolerated statin therapy.

Vico Therapeutics B.V. is a biotechnology company based in Leiden, the Netherlands, founded in 2019. The company specializes in the development of RNA modulating therapies aimed at treating rare neurological disorders. Vico Therapeutics focuses on conditions such as spinocerebellar ataxias, Huntington’s disease, and Rett syndrome, which encompass a range of hereditary and neurodevelopmental disorders. By discovering and developing innovative therapies, the company aims to address significant unmet medical needs in the central nervous system, providing new treatment options for patients and healthcare professionals.

ViCentra B.V., based in Utrecht, the Netherlands, specializes in the development of medical devices, particularly for diabetes management. The company focuses on creating user-friendly and aesthetically pleasing products that aim to enhance the overall experience for individuals managing their health. ViCentra emphasizes the importance of excellent customer experiences and approaches product design with the belief that simplicity and effectiveness lead to better health outcomes. In addition to its operations in the Netherlands, ViCentra also has a presence in the UK, where it continues to innovate in the field of medical devices through dedicated research and development efforts.

Cybin is a biopharmaceutical company dedicated to advancing research and development in psychedelic and medicinal mushrooms. It focuses on creating safe and effective therapeutics for mental health issues, with an emphasis on psilocybin-based products. The company is actively launching these products in jurisdictions where they are permitted and is engaged in clinical studies across North America and other regions. Through strategic partnerships with academic and institutional entities, Cybin seeks to develop novel compounds and delivery mechanisms, aiming to provide innovative treatments for various psychiatric and neurological conditions.

Kiadis Pharma N.V. is a clinical-stage biopharmaceutical company based in Amsterdam, the Netherlands, specializing in the development of cell-based immunotherapy products for blood cancers and inherited blood disorders. The company is currently advancing its product pipeline, which includes K-NK002, an adjunctive immunotherapeutic in Phase II trials for blood cancer patients undergoing haploidentical hematopoietic stem cell transplants, and K-NK003, which is in Phase I/II trials for patients with acute myeloid leukemia who are relapsed or refractory. Additionally, Kiadis Pharma is developing K-NK00X, a preclinical NK-cell therapy candidate aimed at treating various solid tumors. The company is engaged in collaborative efforts with multiple institutions to explore innovative treatments, including a combination of a monoclonal antibody and natural killer cells for COVID-19. Established in 1997, Kiadis Pharma addresses critical unmet medical needs in oncology through its innovative therapeutic approaches.

AM Pharma B.V. is a biopharmaceutical company based in Bunnik, the Netherlands, focused on developing and commercializing novel therapeutics for inflammatory and infectious diseases. Established in 2000, the company specializes in pre-clinical and clinical development using endogenous proteins and peptides derived from the human body. Its key products include alkaline phosphatase, aimed at treating acute kidney injury and ulcerative colitis, and the immune response amplifying peptide hLF1-11, which targets drug-resistant hospital-acquired infections. AM Pharma is committed to providing innovative therapies that enhance patient quality of life by addressing critical medical needs.

Veritas Petroleum Services is a global provider of testing, inspection, and advisory services, operating five laboratories strategically located in the Netherlands, Singapore, Houston, Fujairah, and Manchester. The company specializes in fuel quality testing, bunker quantity surveys, oil condition monitoring, and transformer oil testing, among other services. By offering these solutions, Veritas Petroleum Services assists clients in the marine, power, and renewable sectors to optimize their operational performance. The company focuses on helping its customers improve fuel management, reduce fuel costs, enhance operational efficiency, and comply with environmental regulations.

Caiway is a telecom infrastructure company based in Naaldwijk, Netherlands, specializing in broadband connectivity for over 350,000 households and businesses. The company has expanded its operations in recent years by rolling out fiber networks to underserved municipalities and remote areas. As a regional internet service provider, Caiway offers a comprehensive suite of services, including cable television, broadband internet, and telephony, utilizing advanced cable and fiber infrastructure. Key regions within its operational footprint include Westland, Schiedam, and Almelo, where it aims to deliver reliable networking solutions to enhance connectivity for its customers.

Xeltis AG, established in 2006, is a clinical-stage medical device company based in Zurich, Switzerland, with additional operations in the Netherlands and the USA. The company specializes in developing bio-absorbable heart valves and blood vessels using a proprietary polymer-based technology. Xeltis' RestoreX platform enables the body's natural healing system to develop tissue that replaces the implant, forming a new functional valve or vessel. The company's restorative devices include implantable small diameter blood vessels for hemodialysis and coronary artery bypass graft (CABG) surgery, as well as pulmonary heart valves, with ongoing clinical trials. Xeltis has raised funding from various venture capital firms and European institutions, including a €30 million round in 2021.

DentConnect is a fast-growing platform of dental clinics, with activities in the Netherlands, Belgium, Denmark, Germany and Italy. DentConnect is headquartered in the Netherlands and serves over one million patients through its pan-European network of over 220 clinics. DentConnect acts as a multi-functional service organization for these clinics, allowing the dentists to fully focus on providing patients with the best possible care. DentConnect Shared Service Center supports and facilitates dentists with HR, Finance and administration, quality and care management, procurement, marketing and communication and general management.

TransIP Group B.V., established in 2003 and headquartered in Leiden, Netherlands, specializes in providing web hosting and related services. It caters primarily to tech-savvy customers and IT professionals, offering a range of products including virtual private servers, domain name registration, and web hosting. The company's notable services comprise BladeVPS PureSSD Pro, a self-managed tool with web control panels and operating systems, STACK for online file storage, syncing, and sharing, and SSL certificates for website encryption. Additionally, TransIP provides services like forwarding, big storage, and private network solutions. As of 2019, TransIP operates as a subsidiary of Combell nv.

Onward is a medical technology company focused on developing therapies aimed at enabling functional recovery for individuals with spinal cord injuries. The company is creating an Implantable Neuro-stimulation System (INS) that features real-time motion feedback and utilizes training tools for rehabilitation. Onward has developed two platforms for neurostimulation: ARCIM, an implantable system, and ARCEX, a non-invasive transcutaneous system. To establish its customer base, Onward has targeted the United States and four European markets, namely Germany, France, the United Kingdom, and the Netherlands.

ViCentra B.V., based in Utrecht, the Netherlands, specializes in the development of medical devices, particularly for diabetes management. The company focuses on creating user-friendly and aesthetically pleasing products that aim to enhance the overall experience for individuals managing their health. ViCentra emphasizes the importance of excellent customer experiences and approaches product design with the belief that simplicity and effectiveness lead to better health outcomes. In addition to its operations in the Netherlands, ViCentra also has a presence in the UK, where it continues to innovate in the field of medical devices through dedicated research and development efforts.

Xeltis AG, established in 2006, is a clinical-stage medical device company based in Zurich, Switzerland, with additional operations in the Netherlands and the USA. The company specializes in developing bio-absorbable heart valves and blood vessels using a proprietary polymer-based technology. Xeltis' RestoreX platform enables the body's natural healing system to develop tissue that replaces the implant, forming a new functional valve or vessel. The company's restorative devices include implantable small diameter blood vessels for hemodialysis and coronary artery bypass graft (CABG) surgery, as well as pulmonary heart valves, with ongoing clinical trials. Xeltis has raised funding from various venture capital firms and European institutions, including a €30 million round in 2021.

Xeltis AG, established in 2006, is a clinical-stage medical device company based in Zurich, Switzerland, with additional operations in the Netherlands and the USA. The company specializes in developing bio-absorbable heart valves and blood vessels using a proprietary polymer-based technology. Xeltis' RestoreX platform enables the body's natural healing system to develop tissue that replaces the implant, forming a new functional valve or vessel. The company's restorative devices include implantable small diameter blood vessels for hemodialysis and coronary artery bypass graft (CABG) surgery, as well as pulmonary heart valves, with ongoing clinical trials. Xeltis has raised funding from various venture capital firms and European institutions, including a €30 million round in 2021.

Kiadis Pharma N.V. is a clinical-stage biopharmaceutical company based in Amsterdam, the Netherlands, specializing in the development of cell-based immunotherapy products for blood cancers and inherited blood disorders. The company is currently advancing its product pipeline, which includes K-NK002, an adjunctive immunotherapeutic in Phase II trials for blood cancer patients undergoing haploidentical hematopoietic stem cell transplants, and K-NK003, which is in Phase I/II trials for patients with acute myeloid leukemia who are relapsed or refractory. Additionally, Kiadis Pharma is developing K-NK00X, a preclinical NK-cell therapy candidate aimed at treating various solid tumors. The company is engaged in collaborative efforts with multiple institutions to explore innovative treatments, including a combination of a monoclonal antibody and natural killer cells for COVID-19. Established in 1997, Kiadis Pharma addresses critical unmet medical needs in oncology through its innovative therapeutic approaches.

Argenx is a global immunology company based in the Netherlands, dedicated to enhancing the lives of individuals affected by severe autoimmune diseases and cancer. The company specializes in antibody engineering technology to develop treatments for rare autoimmune conditions. Its lead product, Vyvgart (efgartigimod), received initial approval in the United States in December 2021 for the treatment of generalized myasthenia gravis, followed by subsequent approvals in Europe and Japan in 2022. Through its innovative approaches, Argenx aims to address significant unmet medical needs in the field of immunology.

Atos Medical, founded in 1986, specializes in manufacturing therapeutic devices aimed at enhancing the quality of life for laryngectomized patients. The company produces a range of products, including voice prosthetics, pulmonary rehabilitation devices, adhesives, laryngectomy tubes, and hands-free speaking devices. With its headquarters in Sweden, Atos Medical operates a state-of-the-art clean room and laboratory to support research and development. The company has established a significant international presence, with subsidiaries in multiple countries, including the USA, UK, Germany, Spain, the Netherlands, Belgium, Sweden, and Switzerland, along with exclusive distributors in around 60 countries.

Sapiens Steering Brain Stimulation GmbH is a medical device company focused on advancing deep brain stimulation (DBS) therapy. Founded in 2011 as a spin-out of Royal Philips Electronics, Sapiens operates from offices in Eindhoven, the Netherlands, and Munich, Germany. The company is dedicated to developing a high-resolution, MRI-compatible DBS system designed to enhance patient comfort and improve therapeutic outcomes, particularly for individuals with Parkinson's disease. Sapiens’ innovative approach includes a unique steering brain stimulation system and image-guided programming, both of which are based on patented technologies.

Argenx is a global immunology company based in the Netherlands, dedicated to enhancing the lives of individuals affected by severe autoimmune diseases and cancer. The company specializes in antibody engineering technology to develop treatments for rare autoimmune conditions. Its lead product, Vyvgart (efgartigimod), received initial approval in the United States in December 2021 for the treatment of generalized myasthenia gravis, followed by subsequent approvals in Europe and Japan in 2022. Through its innovative approaches, Argenx aims to address significant unmet medical needs in the field of immunology.

BMEYE B.V. is a Dutch company specializing in non-invasive cardiovascular monitoring technologies. Founded in 2005 and based in Amsterdam, BMEYE focuses on the research and development of innovative medical devices for measuring blood pressure and cardiac output. Its product portfolio includes several advanced monitoring systems such as Finapres, a continuous finger blood pressure monitor; Portapres, an ambulatory version for continuous measurements; and Finometer, a stationary monitor that provides non-invasive brachial pressure and beat-to-beat hemodynamic assessments. Additionally, the company offers Nexfin and ccNexfin monitors, which are designed for cardiology and critical care applications respectively, along with various specialized devices like BeatScope for arterial waveform analysis, Modelflow for aortic flow calculations, and Cardiopres for studying the interplay of electrophysiology and hemodynamics. BMEYE distributes its products through a network of distributors across the Netherlands and international markets.

BMEYE B.V. is a Dutch company specializing in non-invasive cardiovascular monitoring technologies. Founded in 2005 and based in Amsterdam, BMEYE focuses on the research and development of innovative medical devices for measuring blood pressure and cardiac output. Its product portfolio includes several advanced monitoring systems such as Finapres, a continuous finger blood pressure monitor; Portapres, an ambulatory version for continuous measurements; and Finometer, a stationary monitor that provides non-invasive brachial pressure and beat-to-beat hemodynamic assessments. Additionally, the company offers Nexfin and ccNexfin monitors, which are designed for cardiology and critical care applications respectively, along with various specialized devices like BeatScope for arterial waveform analysis, Modelflow for aortic flow calculations, and Cardiopres for studying the interplay of electrophysiology and hemodynamics. BMEYE distributes its products through a network of distributors across the Netherlands and international markets.

Kiadis Pharma N.V. is a clinical-stage biopharmaceutical company based in Amsterdam, the Netherlands, specializing in the development of cell-based immunotherapy products for blood cancers and inherited blood disorders. The company is currently advancing its product pipeline, which includes K-NK002, an adjunctive immunotherapeutic in Phase II trials for blood cancer patients undergoing haploidentical hematopoietic stem cell transplants, and K-NK003, which is in Phase I/II trials for patients with acute myeloid leukemia who are relapsed or refractory. Additionally, Kiadis Pharma is developing K-NK00X, a preclinical NK-cell therapy candidate aimed at treating various solid tumors. The company is engaged in collaborative efforts with multiple institutions to explore innovative treatments, including a combination of a monoclonal antibody and natural killer cells for COVID-19. Established in 1997, Kiadis Pharma addresses critical unmet medical needs in oncology through its innovative therapeutic approaches.

BMEYE B.V. is a Dutch company specializing in non-invasive cardiovascular monitoring technologies. Founded in 2005 and based in Amsterdam, BMEYE focuses on the research and development of innovative medical devices for measuring blood pressure and cardiac output. Its product portfolio includes several advanced monitoring systems such as Finapres, a continuous finger blood pressure monitor; Portapres, an ambulatory version for continuous measurements; and Finometer, a stationary monitor that provides non-invasive brachial pressure and beat-to-beat hemodynamic assessments. Additionally, the company offers Nexfin and ccNexfin monitors, which are designed for cardiology and critical care applications respectively, along with various specialized devices like BeatScope for arterial waveform analysis, Modelflow for aortic flow calculations, and Cardiopres for studying the interplay of electrophysiology and hemodynamics. BMEYE distributes its products through a network of distributors across the Netherlands and international markets.

DNage is a life sciences company founded in 2004 as a spin off from the Department of Genetics of the Erasmus Medical Center Rotterdam. The Company was seed-funded through an equity investment of an international syndicate of venture capitalists including LSP (NL) and Inventages (CH).

Haanpaa Group is a logistics provider specializing in the distribution of liquid chemical products across Europe. Founded in 1949 by Jussi Haanpaa and headquartered in Vantaa, Finland, the company offers a comprehensive range of services, including storage, maintenance, transportation, and delivery of chemical products in several European cities. Haanpaa is also involved in sampling, monitoring, packaging, and tank inspection, catering to industries such as specialty chemicals, pulps and papers, fuels, lubricants, animal feeds, and agricultural commodities. The company has expanded its operations with branches in Finland, Sweden, Norway, Estonia, Russia, and the Netherlands. Since July 2016, Haanpaa operates as a subsidiary of Groupe Samat SA.